Evidence map›Paper›PMID 42340592›Full record

ReviewAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026

Clinical Pharmacology of Plozasiran.

Jessica Huston, Dontia Orey, Kelli Corona, Andrew Ashchi, Andrea Ashchi Lachapelle, Elias Deeb, Alexander Deeb, Rambod Rouhbakhsh, Jason Berner, David Sutton and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jessica HustonDepartment of Pharmacy Education and Practice, College of Pharmacy, University of Florida, 580 W. 8th Street, Jacksonville, FL, 32209, USA.
Dontia OreyEast Coast Institute for Research, 3550 University Blvd S #101, Jacksonville, FL, 32216, USA.
Kelli CoronaDepartment of Pharmacy Education and Practice, College of Pharmacy, University of Florida, 580 W. 8th Street, Jacksonville, FL, 32209, USA.
Andrew AshchiEast Coast Institute for Research, 3550 University Blvd S #101, Jacksonville, FL, 32216, USA.
Andrea Ashchi LachapelleEast Coast Institute for Research, 3550 University Blvd S #101, Jacksonville, FL, 32216, USA.
Elias DeebPhiladelphia College of Osteopathic Medicine - South Georgia Campus, 2050 Tallokas Rd, Moultrie, GA, 31768, USA.
Alexander DeebSidney Kimmel Medical College, Thomas Jefferson University, 1015 Walnut St, Philadelphia, PA, 19107, USA.
Rambod RouhbakhshForrest General Hospital Family Medicine Residency, 415 S. 28th Ave., Hattiesburg, MS, 39401, USA.
Jason BernerGeorgia Mountain Endocrinology, 120 Oakside Ct, Canton, GA, 30114, USA.
David SuttonNortheast Florida Endocrine and Diabetes Associates, 3550 University Blvd S #301, Jacksonville, FL, 32216, USA.
Wasim DeebFirst Choice Endocrinology, 8773 Perimeter Park Ct, Jacksonville, FL, 32216, USA.
Majdi AshchiAshchi Heart and Vascular Center, 3900 University Blvd S, Jacksonville, FL, 32216, USA.
Amir AzarbalAshchi Heart and Vascular Center, 3900 University Blvd S, Jacksonville, FL, 32216, USA.
Rebecca F GoldfadenEast Coast Institute for Research, 3550 University Blvd S #101, Jacksonville, FL, 32216, USA. rg@eastcoastresearch.net.ORCID http://orcid.org/0000-0002-6401-4888

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertriglyceridemia can increase the risk of acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). Patients with familial chylomicronemia syndrome are at an even higher risk of developing pancreatitis due to elevated triglycerides. A pathway involving small interfering RNA that selectively inhibits apolipoprotein C-III (APOC3) messenger RNA through RNA interference is currently being studied to reduce levels of apoC-III and thus, triglycerides. This review presents and discusses the current pharmacokinetic, pharmacodynamics, and clinical and scientific evidence pertaining to plozasiran, a small interfering RNA medicine.

Indexed as

Hyperlipoproteinemia Type IHypertriglyceridemiaRNA, Small InterferingAnimalsApolipoprotein C-IIIAtherosclerosisHumansPancreatitisRNA InterferenceApolipoprotein C-IIIpatisiranplozasiranRNA, Small Interfering

Identifiers

PMID42340592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.